Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo

Immunology Letters

Volumn 148, Issue 2, 2012, Pages 126-132

  Ni, Guoying ^a,b   Wang, Yuejian ^c   Wu, Xiaolian ^c   Wang, Xiongfei ^c   Chen, Shu ^c   Liu, Xiaosong ^a,c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Health Supervision Institute   (China)

^c THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

Author keywords

Graphene oxide; IL10; Immunotherapy

Indexed keywords

ANTIBODY CONJUGATE; CD86 ANTIGEN; GAMMA INTERFERON; GRAPHENE OXIDE; GRAPHENE OXIDE GAMMA INTERFERON INTERLEUKIN 10 RECEPTOR ANTIBODY CONJUGATE; GRAPHENE OXIDE INTERLEUKIN 10 RECEPTOR ANTIBODY CONJUGATE; INTERLEUKIN 10 RECEPTOR ANTIBODY; INTERLEUKIN 12P40; LIPOPOLYSACCHARIDE; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ABSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; SLOW DRUG RELEASE; SPLEEN CELL; TH1 CELL;

ANIMALS; ANTIBODIES; FEMALE; GRAPHITE; IMMUNIZATION; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P40; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; RECEPTORS, INTERLEUKIN-10; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84869809002     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.10.001     Document Type: Article

References (34)

1. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2011, 33:492-503.
2. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002, 168:926-932.
3. + T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 2009, 183:51-58.
4. + T cell response. J Immunol 2007, 178:5429-5433.
5. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010, 10:170-181.
6. Sato T., Terai M., Tamura Y., Alexeev V., Mastrangelo M.J., Selvan S.R. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011, 51:170-182.
7. Zhou G., Drake C.G., Levitsky H.I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006, 107:628-636.
8. Sanchez V.C., Jachak A., Hurt R.H., Kane A.B. Biological interactions of graphene-family nanomaterials: an interdisciplinary review. Chem Res Toxicol 2011, 25:15-34.
9. Zhang L., Xia J., Zhao Q., Liu L., Zhang Z. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small 2010, 6:537-544.
10. Yang K., Zhang S., Zhang G., Sun X., Lee S.T., Liu Z. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett 2010, 10:3318-3323.
11. Vicari A.P., Chiodoni C., Vaure C., Ait-Yahia S., Dercamp C., Matsos F., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002, 196:541-549.
12. Jarnicki A.G., Conroy H., Brereton C., Donnelly G., Toomey D., Walsh K., et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008, 180:3797-3806.
13. Liu X.S., Xu Y., Hardy L., Khammanivong V., Zhao W., Fernando G.J., et al. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol 2003, 171:4765-4772.
14. Moon J.J., Suh H., Polhemus M.E., Ockenhouse C.F., Yadava A., Irvine D.J. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS ONE 2012, 7:e31472.
15. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol 2011, 9:55.
16. Krishnamachari Y., Geary S.M., Lemke C.D., Salem A.K. Nanoparticle delivery systems in cancer vaccines. Pharm Res 2011, 28:215-236.
17. Wen Z.S., Xu Y.L., Zou X.T., Xu Z.R. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs 2011, 9:1038-1055.
18. Matsuo K., Koizumi H., Akashi M., Nakagawa S., Fujita T., Yamamoto A., et al. Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release 2011, 152:310-316.
19. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc 2008, 130:10876-10877.
20. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
21. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
22. + T effectors. J Immunol 2006, 177:6962-6973.
23. Knutson K.L., Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54:721-728.
24. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006, 12:1301-1309.
25. Wilson E.B., Brooks D.G. The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol 2011, 350:39-65.
26. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., Crotty S., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006, 203:2461-2472.
27. Liu X.S., Dyer J., Leggatt G.R., Fernando G.J., Zhong J., Thomas R., et al. Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J Immunol 2006, 177:2873-2879.
28. Sellon R.K., Tonkonogy S., Schultz M., Dieleman L.A., Grenther W., Balish E., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998, 66:5224-5231.
29. Iyer S.S., Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol 2012, 32:23-63.
30. Segal B.M., Dwyer B.K., Shevach E.M. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998, 187:537-546.
31. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005, 65:3437-3446.
32. Fukamachi T., Chiba Y., Wang X., Saito H., Tagawa M., Kobayashi H. Tumor specific low pH environments enhance the cytotoxicity of lovastatin and cantharidin. Cancer Lett 2010, 297:182-189.
33. Mumm J.B., Emmerich J., Zhang X., Chan I., Wu L., Mauze S., et al. IL10 elicits IFNγ dependent tumour immune surveillance. Cancer Cell 2011, 20:781-796.
34. + T cells De Novo infiltration from secondary yymphoid Organs. Cancer Res 2012, 72:3570-3581.